Effect of CXCR2 Inhibition on Behavioral Outcomes and Pathology in Rat Model of Neuromyelitis Optica

Figure 3

Astrocyte damage is not attenuated by treatment with CXCR2 antagonist, SCH527123. Examples of focal astrocyte death demonstrated by loss of AQP4 (brown stain (a)) or GFAP (brown stain (b)) immunohistochemistry in adjacent tissue sections (). In the first cohort (c), AQP4- and GFAP-depleted lesions (left and right y-axis, respectively) were not significantly decreased by SCH527123 treatment at 30 mg/kg (red triangles) compared to vehicle-treated rats (green circles). Depo-Medrol treatment at 10 mg/kg (blue squares) significantly decreased lesion load (). In the second cohort (d), there was no significant astrocytic protective effect of SCH527123, even when the groups were subdivided by IgG deposition, where the “hi IgG” animals showed relatively higher levels of IgG deposition and AQP4/GFAP loss compared to the “low IgG” animals.

(a)

(b)

(c)

(d)